{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:56:19Z","timestamp":1792007779583,"version":"4.4.0"},"reference-count":34,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The cornerstone treatment for primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA), but many patients exhibit an incomplete response, leading to disease progression. Risk prediction models like the GLOBE and UK-PBC scores hold promise for patient stratification and management. We aimed to independently assess the predictive accuracy of these risk scores for UDCA response in a prospective U.S. cohort. Methods: We conducted a prospective cohort study at a U.S. liver center, monitoring UDCA-treated PBC patients over a one-year follow-up. We evaluated the predictive efficacy of the GLOBE and UK-PBC scores for UDCA treatment response, comparing them to the Paris II criteria. Efficacy was assessed using univariate and multivariate analyses, followed by prognostic performance evaluation via receiver operating characteristic (ROC) curve analysis. Results: We evaluated 136 PBC patients undergoing UDCA therapy. Based on the Paris II criteria, patients were categorized into UDCA full-response and non-response groups. The GLOBE score identified a non-responder rate of 18% (p = 0.205), compared to 20% (p = 0.014) with the Paris II criteria. Multivariate analysis, adjusted for age and biochemical markers, showed that both the GLOBE and UK-PBC scores were strongly associated with treatment response (p &lt; 0.001). The area under the ROC curve was 0.87 (95% CI 0.83\u22120.95) for the GLOBE score and 0.94 (95% CI 0.86\u22120.99) for the UK-PBC risk score. Conclusions: Our study demonstrates that GLOBE and UK-PBC scores effectively predict UDCA treatment response in PBC patients. The early identification of patients at risk of an incomplete response could improve treatment strategies and identify patients who may need second-line therapies.<\/jats:p>","DOI":"10.3390\/jcm13154497","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T08:14:46Z","timestamp":1722500086000},"page":"4497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The External Validation of GLOBE and UK-PBC Risk Scores for Predicting Ursodeoxycholic Acid Treatment Response in a Large U.S. Cohort of Primary Biliary Cholangitis Patients"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-2294","authenticated-orcid":false,"given":"Ana","family":"Marenco-Flores","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1469-8176","authenticated-orcid":false,"given":"Natalia","family":"Rojas Amaris","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Kahan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7148-5450","authenticated-orcid":false,"given":"Leandro","family":"Sierra","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4158-9264","authenticated-orcid":false,"given":"Romelia","family":"Barba Bernal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University System, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4008-9770","authenticated-orcid":false,"given":"Esli","family":"Medina-Morales","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Goyes","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilas","family":"Patwardhan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-0416","authenticated-orcid":false,"given":"Alan","family":"Bonder","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: Epidemiology, prognosis, and treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5152\/tjg.2023.22239","article-title":"Management of primary biliary cholangitis: Current treatment and future perspectives","volume":"34","author":"Ferrigno","year":"2023","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","article-title":"Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients","volume":"78","author":"Christensen","year":"1980","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","article-title":"Natural history of primary biliary cholangitis in the ursodeoxycholic acid era","volume":"22","author":"Goel","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103027","DOI":"10.1016\/j.jaut.2023.103027","article-title":"Breach of tolerance versus burden of bile acids: Resolving the conundrum in the immunopathogenesis and natural history of primary biliary cholangitis","volume":"136","author":"Yamashita","year":"2023","journal-title":"J. Autoimmun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/hep4.1180","article-title":"Clinical application of the Globe and united kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis","volume":"2","author":"Carbone","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.cgh.2020.06.062","article-title":"Definition and management of patients with primary biliary cholangitis and an incomplete response to therapy","volume":"19","author":"Corpechot","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12072-022-10431-7","article-title":"Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: An early criterion","volume":"17","author":"Yang","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_11","first-page":"149","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"147","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2015","journal-title":"Hepatology"},{"key":"ref_13","first-page":"1196","article-title":"Ursodeoxycholic acid treatment\u2013induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis","volume":"118","author":"Corpechot","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/hep4.1186","article-title":"External validation of the united kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with Ursodeoxycholic acid","volume":"2","author":"Cheung","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: The additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jgh3.12223","article-title":"Evaluation of the united kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population","volume":"4","author":"Alomari","year":"2019","journal-title":"JGH Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.06.006","article-title":"Risk stratification and prognostic modelling in primary biliary cholangitis","volume":"34\u201335","author":"Goet","year":"2018","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/liv.13294","article-title":"Old and new treatments for primary biliary cholangitis","volume":"37","author":"Chascsa","year":"2017","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2020.0028","article-title":"Current understanding of primary biliary cholangitis","volume":"27","author":"Tanaka","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. data from a national registry of liver disease","volume":"9","author":"Liberal","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2010.09.004","article-title":"Pathogenesis of cholestatic liver disease and therapeutic approaches","volume":"139","author":"Hirschfield","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.aohep.2018.11.006","article-title":"Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features","volume":"18","author":"Cardoso","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.23210","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study","volume":"50","author":"Myers","year":"2009","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gazda, J., Drazilova, S., Janicko, M., Grgurevic, I., Kanizaj, T.F., Koller, T., Bodorovska, B., Bozin, T., Mijic, M., and Rob, Z. (2021). Prognostic factors in primary biliary cholangitis: A retrospective study of Joint Slovak and Croatian cohort of 249 patients. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060495"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"FSO975","DOI":"10.2144\/fsoa-2023-0203","article-title":"Prognostic scores in primary biliary cholangitis","volume":"10","author":"Tababi","year":"2024","journal-title":"Future Sci. OA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.14309\/ajg.0000000000001285","article-title":"A comparison of prognostic scores (Mayo, UK-PBC, and globe) in primary biliary cholangitis","volume":"116","author":"Goet","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_30","first-page":"1","article-title":"Prognostic scores for Ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation","volume":"24","author":"Lytvyak","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to Ursodeoxycholic acid","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.dld.2022.12.010","article-title":"Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis","volume":"55","author":"Gazda","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1038\/ctg.2017.23","article-title":"Prognostic factors for Transplant-free survival and validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid","volume":"8","author":"Cheung","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"714","DOI":"10.5009\/gnl18271","article-title":"Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio","volume":"12","author":"Yoo","year":"2018","journal-title":"Gut Liver"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:27:47Z","timestamp":1760110067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":34,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13154497"],"URL":"https:\/\/doi.org\/10.3390\/jcm13154497","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}